Dr. Ramesh Rengan joined the Department of Radiation Oncology as an Associate Professor in April of 2013 and was appointed as the Medical Director of the SCCA Proton Therapy Center in January 2014. He joined the tumor vaccine group in April 2013. He is a graduate of the University of Michigan with an M.D. and Ph.D in Biological Chemistry. He completed his training in Radiation Oncology at Memorial Sloan-Kettering Cancer Center in July of 2006. He served on the faculty of the University of Pennsylvania in 2006 and as the Chief of the Thoracic service from July of 2010 through April 2013. His clinical interests include thoracic malignancies, melanomas, and other solid tumors. Dr Rengan has developed a number of clinical and translational research protocols including recent completion of a phase II therapeutic trial of Nelfinavir with concurrent chemoradiotherapy in locally advanced NSCLC. He serves as principal investigator for an ongoing phase I/II trial examining the role of SBRT in conjunction with ipilimumab for patients with advanced melanoma. His current area of active research interest is to work in partnership with the CVI to develop an approach to utilize radiation treatment to elicit a tumor-specific immune response in patients with metastatic disease.
Ramesh Rengan, MD, PhD
Medical Director, SCCA Proton Therapy Center